Jennifer Markarian

Time- and cost-savings benefits help drive increased use of single-use, disposable systems in biopharmaceutical manufacturing.

European and US associations call for continued vigilance against the threat of counterfeit medicines.

Combustible dust is a fire and explosion hazard in many industries that handle dusty materials, including pharmaceuticals.

Human Genome Sciences rejects GlaxoSmithKline offer to acquire the company and issues a poison pill to prevent a takeover.

The biopharmaceutical industry is increasingly turning to disposable, single-use systems that offer flexibility and cost benefits.

Advances in process analytical technology and in defining lots for release are key for enabling use of continuous processes in solid-dosage manufacturing.

The growing use of high-potency APIs is leading to changes in how the pharmaceutical industry looks at containment.

Critical issues that should be considered when scaling up a hot-melt extrusion process.

Modular factory concepts, which take flexible manufacturing to the next level, are beginning to take hold in the biopharmaceutical industry.

On Mar. 12, 2012, FDA released a draft guidance document for industry direct-to-consumer television advertisements that describes FDA's plans for implementing predissemination review.

With the increasing use of hot-melt extrusion, extruder manufacturers have developed mid-size twin-screw extruders that facilitate process development and scale-up to commercial processes.

Pfizer announced a decrease in fourth-quarter revenues, but a slight increase in full-year 2011 revenues in its financial report on Jan. 31, 2012.